ALDR Alder BioPharmaceuticals, Inc.

16.15
-0.90  -5%
Previous Close 17.05
Open 17.00
Price To book 2.99
Market Cap 814.12M
Shares 50,410,000
Volume 582,873
Short Ratio 15.29
Av. Daily Volume 595,725

SEC filingsSee all SEC filings

  1. 8-K - Current report 17874903
  2. DEF 14A - Other definitive proxy statements 17795742
  3. 8-K - Current report 17789203
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17788956
  5. CT ORDER - Confidential treatment order 17755856

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 PROMISE 2 initiation announced November 28, 2016. Data due 1H 2018.
ALD403 - PROMISE 2
Frequent episodic migraine
Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403
Chronic Migraine
Phase 3 PROMISE 1 topline data due 2Q 2017.
ALD403 - PROMISE 1
Frequent episodic migraine

Latest News

  1. Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint
  2. Why These Drug Stocks May Surge
  3. Lilly migraine treatment meets main goal in late-stage studies
  4. Alder BioPharmaceuticals® to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
  5. Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALDR-US : May 8, 2017
  6. 3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash
  7. [$$] Three Top Picks in Smaller Pharma
  8. Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo
  9. Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting
  10. Alder BioPharmaceuticals posts 1Q loss
  11. Alder Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:ALDR) : April 27, 2017
  12. Alder BioPharmaceuticals® Announces First Quarter 2017 Financial and Operating Results
  13. Investor Network: Alder Biopharmaceuticals, Inc. to Host Earnings Call
  14. Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALDR-US : April 26, 2017
  15. Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting
  16. Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results
  17. Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors
  18. Alder BioPharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
  19. Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALDR-US : March 21, 2017
  20. Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALDR-US : March 9, 2017